PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 3849381

Sequential colour mapping system of brain potentials.

M H Giard·F Peronnet·J Pernier·F Mauguiere·O Bertrand
View original source ↗Export metadata ↓

Abstract

We present a colour mapping system for the visualization of both the spatial scalp distribution and the temporal evolution of brain potentials. The system is applicable to recordings of auditory, visual and somatosensory potentials. It uses a Tektronix 4113 colour terminal connected to a Solar 16 (SEMS) mini-computer. The brain potentials are recorded on up to 16 scalp electrodes. The gain and the baseline are corrected separately on each channel. At each point of the scalp the potential is reconstructed by a linear interpolation of the measured potentials of the four nearest electrodes. Simultaneously n2 (1 less than n less than 8) colour maps can be presented on the screen. This allows the study of the temporal evolution of full scalp evoked potentials. The user chooses the two extreme latencies defining the time window to be explored and the latencies of the maps are regularly time-spaced within this window. In a typical case, in which four maps are desired, the latencies of the maps can be chosen independently. The 16-colour palette is predetermined but the user has three possibilities to establish the correspondence between the electrical potential and the colours. Examples are shown in the visual and somatosensory stimulation modalities. The advantages and limitations of such a representation are discussed.

Explore related subjects

BrainComputersElectrodesEvoked PotentialsEvoked Potentials, AuditoryEvoked Potentials, SomatosensoryEvoked Potentials, VisualHumansMinicomputersTime FactorsJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

M H Giard, F Peronnet, J Pernier, F Mauguiere, O Bertrand. 1985. Sequential colour mapping system of brain potentials.. https://doi.org/10.1016/0169-2607(85)90040-9

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2026

A MAGIBU-based model for pediatric and juvenile CNS tumors: an in-house epigenetic decision-support framework compared with online DNA methylation classifiers.

Background: DNA methylation profiling is a tool that provides key support for central nervous system (CNS) tumor classification. However, diagnostically ambiguous pediatric cases may result in discordant outputs across classifiers. We developed MAGIBU, a cross-platform, projection-based framework that embeds individual methylomes into a fixed CNS reference landscape, ranking diagnostic entities by local epigenetic proximity to support clinician-led integrative diagnosis. Methods: As a proof-of-concept, we evaluated MAGIBU in eight morphologically challenging pediatric/juvenile CNS tumors with unresolved diagnoses after institutional and central pathology review. To establish a benchmark in the absence of a definitive histopathological ground truth, a consensus epigenetic reference was defined a priori for cases showing concordant results between the Heidelberg CNS Tumor Methylation Classifier and Methylscape Analysis. Comparisons were also performed with Epigenomic Digital Pathology (EpiDiP). To validate MAGIBU beyond this discovery cohort, performance was assessed at the family level across the CNS methylation spectrum (n = 678, 28 methylation families), on non-array platforms (whole-genome bisulfite sequencing and Oxford Nanopore), and in a focused analysis of the low-grade glioma and diffuse midline glioma compartment across four independent cohorts (n = 670). Results: In the discovery cohort, MAGIBU achieved high concordance with the consensus reference (Cohen's κ = 0.855), outperforming EpiDiP (κ = 0.278), which frequently placed low-grade tumors in proximity to higher-grade reference regions. Conclusions: MAGIBU provides a stable, quantitative differential diagnosis framework that mitigates the limitations of rigid categorical assignments. By leveraging a distance-based proximity metric, it offers a transparent decision-support tool that integrates effectively with clinical, radiological, and molecular data. While performance is inherently dependent on reference atlas composition, MAGIBU represents a robust complementary approach for the diagnostic workup of ambiguous CNS tumors.

Brain↗
PubMed2021

1q21.1 distal copy number variants are associated with cerebral and cognitive alterations in humans.

Low-frequency 1q21.1 distal deletion and duplication copy number variant (CNV) carriers are predisposed to multiple neurodevelopmental disorders, including schizophrenia, autism and intellectual disability. Human carriers display a high prevalence of micro- and macrocephaly in deletion and duplication carriers, respectively. The underlying brain structural diversity remains largely unknown. We systematically called CNVs in 38 cohorts from the large-scale ENIGMA-CNV collaboration and the UK Biobank and identified 28 1q21.1 distal deletion and 22 duplication carriers and 37,088 non-carriers (48% male) derived from 15 distinct magnetic resonance imaging scanner sites. With standardized methods, we compared subcortical and cortical brain measures (all) and cognitive performance (UK Biobank only) between carrier groups also testing for mediation of brain structure on cognition. We identified positive dosage effects of copy number on intracranial volume (ICV) and total cortical surface area, with the largest effects in frontal and cingulate cortices, and negative dosage effects on caudate and hippocampal volumes. The carriers displayed distinct cognitive deficit profiles in cognitive tasks from the UK Biobank with intermediate decreases in duplication carriers and somewhat larger in deletion carriers-the latter potentially mediated by ICV or cortical surface area. These results shed light on pathobiological mechanisms of neurodevelopmental disorders, by demonstrating gene dose effect on specific brain structures and effect on cognitive function.

Brain↗